Group 1 - The company, Yaoshi Technology, announced on the evening of September 5 that its fourth board of directors held its tenth meeting and approved the proposal regarding the adjustment of expected daily related transactions for the year 2025 [2]

Market Performance - On September 5, the AI medical sector rose by 1.53%, with Yaoshi Technology leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Stock Performance - The top-performing stocks in the AI medical sector included: - Yaoshi Technology (300725) with a closing price of 44.21, up 3.85% [1] - ZheShu Culture (600633) with a closing price of 14.44, up 3.74% [1] - MaiDi Technology (603990) with a closing price of 14.64, up 3.24% [1] - Other notable stocks included Hongbo Pharmaceutical (301230) at 37.89, up 3.21%, and Jiahe Meikang (688246) at 31.20, up 2.80% [1] Capital Flow - The AI medical sector saw a net inflow of 56.49 million yuan from institutional investors, while retail investors experienced a net outflow of 50.12 million yuan [2] - The capital flow for specific stocks showed: - Meinian Health (002044) had a net inflow of 39.11 million yuan from institutional investors [3] - MaiDi Technology (603990) had a net inflow of 19.26 million yuan from institutional investors [3] - ZheShu Culture (600633) had a net inflow of 5.19 million yuan from institutional investors [3]

Core Viewpoint - Nanjing PharmaBlock Technology Co., Ltd. has announced the early redemption of its convertible bonds ("PharmaBlock Convertible Bonds") due to the stock price exceeding the specified threshold, aiming to reduce financial costs and expenses [2][7]. Group 1: Convertible Bond Issuance and Redemption - The company issued 11.5 million convertible bonds at a face value of 100 RMB each, raising a total of 1.15 billion RMB on April 20, 2022 [2][3]. - The bonds are set to be redeemed at a price of 100.62 RMB per bond, which includes accrued interest calculated based on a 1.5% annual interest rate [8][9]. - The redemption was triggered as the stock price was above 130% of the conversion price for at least 15 trading days [6][7]. Group 2: Conversion Price Adjustments - The conversion price was adjusted from 92.98 RMB to 92.88 RMB after a cash dividend distribution on June 13, 2022 [3][4]. - Subsequent adjustments were made, with the conversion price being lowered to 34.20 RMB as of June 14, 2024, based on stock trading averages [4][5]. - The latest conversion price before redemption is set at 33.61 RMB per share [6]. Group 3: Redemption Process and Timeline - The redemption process includes a series of announcements leading up to the redemption date, with trading of the bonds ceasing on September 15, 2025 [9]. - The actual redemption date is September 18, 2025, with funds expected to reach bondholders' accounts by September 25, 2025 [9][10]. - The company will publish the redemption results and delisting announcement within seven trading days after the redemption [9].

Group 1 - The company has adjusted its estimated daily related party transactions for the year 2025, increasing the total expected amount from 79.6 million yuan to include an additional 1.5 million yuan for sales to a related party [1][2][3] - The revised expected amount for sales of goods and services to Jiangsu Nanchuang Chemical and Life Health Research Institute Co., Ltd. has increased from 1 million yuan to 2.5 million yuan [1][3] - The adjustments were approved by the company's independent directors before being submitted to the board for review, ensuring compliance with relevant regulations [2][6] Group 2 - The company’s total expected related party transactions for 2025 include purchasing goods and services up to 2.6 million yuan, selling goods and providing services up to 75.3 million yuan, and renting assets and paying utility fees up to 1.7 million yuan [1][2] - The related party, Jiangsu Nanchuang Chemical and Life Health Research Institute Co., Ltd., has a registered capital of 12.6111 million yuan and is involved in the research, production, and sales of pharmaceuticals and medical devices [3][4] - The company confirms that the pricing for these transactions is based on market rates and does not harm the interests of non-related shareholders [5][6]

Group 1 - The board of directors of Nanjing Yaoshi Technology Co., Ltd. held its tenth meeting of the fourth session on September 5, 2025, via electronic communication, with all seven directors present [1][2] - The board approved a proposal to increase sales and service provision to related parties by an estimated amount of 1.5 million yuan based on actual business needs [1] - The proposal was reviewed and approved by the independent directors in a separate meeting prior to the board meeting [1]

3、停止交易日：2025 年 9 月 15 日 4、赎回登记日：2025 年 9 月 17 日 | 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-082 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于提前赎回药石转债的第十六次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、"药石转债"赎回价格：100.62 元/张（债券面值加当期应计利息，当期 年利率为 1.5%，且当期利息含税），扣税后的赎回价格以中国证券登记结算有 限责任公司深圳分公司（以下简称"中国结算"）核准的价格为准。 2、赎回条件满足日：2025 年 8 月 14 日 5、停止转股日：2025 年 9 月 18 日 6、赎回日：2025 年 9 月 18 日 7、发行人资金到账日（到达中国结算账户）：2025 年 9 月 23 日 8、投资者赎回款到账日：2025 年 9 月 25 日 9、赎回类别：全部赎回 10、本次赎回完成后，"药石转债"将在深圳证券交 ...

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-081 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于调整 2025 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 日常关联交易基本情况 （一）前期已预计 2025 年度日常关联交易情况 南京药石科技股份有限公司（以下简称 "公司"）于 2025 年 4 月 24 日召开 第四届董事会第四次会议、第四届监事会第四次会议，审议通过了《关于 2024 年度日常关联交易确认及 2025 年度日常关联交易额度预计的公告》，公司及子公 司因业务发展的需要，预计 2025 年度公司可能发生的关联交易不超过 7,960 万 元，其中向关联方采购商品及劳务不超过 260 万元；向关联方销售商品、提供劳 务不超过 7,530 万元，向关联方租入资产、支付物业费及水电费等不超过 170 万 元，具体内容见公司 2025 年 4 月 25 日披露于巨潮资讯网的《关于 2024 年度日 ...

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-080 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 第四届董事会第十次会议决议公告 表决结果： 7 票同意， 0 票反对， 0 票弃权 二、 备查文件 会议在保证所有董事充分发表意见的前提下，以投票表决方式通过了以下议 案： 1、审议通过了《关于调整 2025 年度日常关联交易预计的议案》 经审核，董事会同意公司根据实际经营与业务发展需要增加向关联方销售商 品、提供劳务预计金额 150 万元。 本议案已经第四届董事会独立董事专门会议 2025 年第二次会议审议通过。 具 体 内 容 详 见 公 司 于 创 业 板 信 息 披 露 网 站 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的相关公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京药石科技股份有限公司（以下简称"公司"）第四届董事会第十次会议 于2025年9月5日以电子通信方式召开并表决。会议通知已于20 ...

Group 1 - The core announcement from Yaoshi Technology indicates that the "Yaoshi Convertible Bonds" will be forcibly redeemed at a price of 100.62 CNY per bond if not converted by the market close on September 17, 2025 [1] - The current market price of the "Yaoshi Convertible Bonds" is significantly different from the redemption price, which raises concerns for bondholders [1] - Investors are advised to convert their bonds within the specified period to avoid potential losses [1]

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-079 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于提前赎回药石转债的第十五次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 6、赎回日：2025 年 9 月 18 日 7、发行人资金到账日（到达中国结算账户）：2025 年 9 月 23 日 11、债券持有人若转股，需开通创业板交易权限。投资者不符合创业板股票 适当性管理要求的，不能将所持"药石转债"转换为股票，特提请投资者关注不 能转股的风险。 1、"药石转债"赎回价格：100.62 元/张（债券面值加当期应计利息，当期 年利率为 1.5%，且当期利息含税），扣税后的赎回价格以中国证券登记结算有 限责任公司深圳分公司（以下简称"中国结算"）核准的价格为准。 2、赎回条件满足日：2025 年 8 月 14 日 3、停止交易日：2025 年 9 月 15 日 4、赎回登记日：2025 年 9 月 17 日 5、停止转股日：2 ...